Definium Therapeutics, Inc. is trading 4.7% up at $24.34, extending a multi-day rebound as the stock benefits from institutional accumulation and a broader risk-on sentiment in the biotech sector.
- GEODE Capital Management disclosed a new $46.0 million position, providing a bullish catalyst for the stock despite a lack of fresh company-specific news on June 11, 2026.
- The move follows a period of heightened volatility in biotech names, with traders now leaning into sector momentum and institutional fund interest rather than new fundamentals.